INCLISIRAN EFFECTIVE IN LOWERING LDL-C OF PATIENTS AT VERY OR EXTREMELY HIGH RISK FOR CARDIOVASCULAR DISEASE

The Clinical Practice Guidelines on Management of Dyslipidemia 2023 has set lower target low-density lipoprotein-cholesterol (LDL-C) levels for patients at very high cardiovascular (CV) risk and created new target LDL-C levels for patients at extremely high CV risk in terms of secondary prevention. Clearly, these updated treatment targets call for new and effective treatments. A prominent cardiologist explains the management of patients in the two risk groups using Sybrava® (inclisiran), a new injectable form of lipid-modifying agent.